%0 Journal Article
%T What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A£¿systematic review
%A Alex McKeown
%A Amanda Ly
%A Anders Gustavsson
%A Anna Ponjoan
%A Buket £¿zt¨¹rk
%A Catherine Reed
%A Cathie Sudlow
%A Christin Bexelius
%A Christoph Jindra
%A Christophe Bintener
%A Emilse Roncancio-Diaz
%A Enrico Fantoni
%A Helen Baldwin
%A Isabella F. J£¿rgensen
%A Josep Garre-Olmo
%A Mia Nelson
%A Michael Smith
%A Michele H. Potashman
%A Olin Janssen
%A Stephanie Vos
%A the ROADMAP consortium
%J Archive of "Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring".
%D 2019
%R 10.1016/j.dadm.2018.12.003
%X Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of the disease most relevant to key stakeholders
%K Alzheimer's Disease
%K Mild cognitive impairment
%K Outcomes
%K Systematic review
%K Qualitative
%K Quantitative
%K Quality of life
%K Memory
%K Activities of daily living
%K Autonomy
%K Burden
%K Patients
%K Caregivers
%K Healthcare professionals
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411507/